SYH2059 not checked
InnovStone Therapeutics Limited
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Take twice daily, about 12 hours apart, after meals, for 12 weeks.”In the company’s words, NCT07600021 on ClinicalTrials.gov
- Tested for
- Idiopathic Pulmonary Fibrosis
- Main trialPhase 2
- “This is a multicenter, randomized, double-blind, placebo-controlled Phase II study. It Aims aims to evaluate the efficacy and safety of different doses of SYH2059 tablets compared with placebo in adult patients with IPF, observe the PK profile of SYH2059 tablets in adult IPF patients, and assess the population pharmacokinetic (PPK) profile, exposure-response (E-R) relationship, as well as the changing trends of blood biomarkers.”In the company’s words, NCT07600021 on ClinicalTrials.gov
Other drugs for Idiopathic Pulmonary Fibrosis
- SC1011JOYO Pharma · Phase 2/3
- NerandomilastBoehringer Ingelheim · Phase 3
- NAL ERTrevi Therapeutics · Phase 3
- AK3280Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 3
- TDI01Beijing Tide Pharmaceutical Co., Ltd · Phase 3
- INS018_055InSilico Medicine Hong Kong Limited · Phase 3
Coming up2
- 31 DecPhase 1 trial completes · ClinicalTrials.gov
- 30 Oct 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 30 Oct 2027 | A Phase II Study to Evaluate the Efficacy and Safety of SYH2059 Tablets in Adult Patients With Idiopathic Pulmonary Fibrosis | |
| Phase 1Not yet recruiting | 31 Dec 2026 | A Single- and Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2059 Powder for Inhalation |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026